Oncological management of unresectable liver metastases

Digestive Diseases

Volumn 30, Issue SUPPL.2, 2012, Pages 137-142

  Prenen, Hans ^a   Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Colorectal cancer; Unresectable liver metastases

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TIME FACTORS;

EID: 84870847395     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342047     Document Type: Conference Paper

References (39)

1. Tournigand C, André T, Achille E, Lledo G,Flesh M, Mery-Mignard D, Quinaux E, CouteauC, Buyse M, Ganem G, Landi B, Colin P,Louvet C, de Gramont A: FOLFIRI followedby FOLFOX6 or the reverse sequence inadvanced colorectal cancer: a randomizedGERCOR study. J Clin Oncol 2004; 22: 229-237.
2. Welch S, Spithoff K, Rumble RB, Maroun J,Gastrointestinal Cancer Disease Site Group:Bevacizumab combined with chemotherapyfor patients with advanced colorectal cancer: A systematic review. Ann Oncol 2010; 21:1152-1162.
3. Van Cutsem E, Köhne CH, Hitre E, ZaluskiJ, Chang Chien CR, Makhson A, D'Haens G,Pintér T, Lim R, Bodoky G, Roh JK, FolprechtG, Ruff P, Stroh C, Tejpar S, Schlichting M,Pippgen J, Rougier P: Cetuximab and chemotherapyas initial treatment for metastaticcolorectal cancer. N Engl J Med 2009; 360:1408-1417.
4. Bokemeyer C, Bondarenko I, Makhson A,Hartmann JT, Aparicio J, de Braud F, DoneaS, Ludwig H, Schuch G, Stroh C, Loos AH,Zubel A, Koralewski P: Fluorouracil, leucovorin,and oxaliplatin with and without cetuximabin the first-line treatment of metastaticcolorectal cancer. J Clin Oncol 2009;27: 663-671.
5. Douillard JY, Siena S, Cassidy J, Tabernero J,Burkes R, Barugel M, Humblet Y, Bodky G,Cunningham D, Jassem J, Rivera F, KocakovaI, Ruff P, Blasinska-Morawiec M, SmakalM, Canon JL, Rother M, Oliner KS, Wolf M,Gansert J: Randomized, phase III trial of panitumumabwith infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versusFOLFOX4 alone as first-line treatment inpatients with previously untreated metastaticcolorectal cancer: the PRIME study. J ClinOncol 2010; 28: 4697-4705.
6. Jonker DJ, O'Callaghan CJ, Karapetis CS,Zalcberg JR, Tu D, Au HJ, Berry SR, KrahnM, Price T, Simes RJ, Tebbutt NC, van HazelG, Wierzbicki R, Langer C, Moore MJ: Cetuximabfor the treatment of colorectal cancer.N Engl J Med 2007; 357: 2040-2048.
7. Cunningham D, Humblet Y, Siena S, KhayatD, Bleiberg H, Santoro A, Bets D, Mueser M,Harstrick A, Verslype C, Chau I, Van CutsemE: Cetuximab monotherapy and cetuximabplus irinotecan in irinotecan-refractory metastasticcolorectal cancer. N Engl J Med2004; 351: 337-345.
8. Kemeny N: Presurgical chemotherapy in patientsbeing considered for liver resection.Oncologist 2007; 12: 825-839.
9. Nordlinger B, Rougier P: Liver metastasesfrom colorectal cancer: the turning point. JClin Oncol 2002; 20: 1442-1445.
10. Livermetsurvey, an international registry oncolorectal liver metastases. www.livermetsurvey.org11 Abdalla EK, Vauthey JN, Ellis LM, Ellis V,Pollock R, Broglio KR, Hess K, Curley SA:Recurrence and outcomes following hepaticresection, radiofrequency ablation, andcombined resection/ablation for colorectalliver metastases. Ann Surg 2004; 239: 818-825.
11. Adam R, Delvart V, Pascal G, Valeanu A,Castaing D, Azoulay D, Giacchetti S, PauleB, Kunstlinger F, Ghémard O, Levi F, BismuthH: Rescue surgery for unresectablecolorectal liver metastases downstaged bychemotherapy: a model to predict long-termsurvival. Ann Surg 2004; 240: 644-657.
12. Jaeck D, Oussoultzoglou E, Rosso, Greget M,Weber JC, Bachellier P: A two-stage hepatectomyprocedure combined with portal veinembolization to achieve curative resectionfor initially unresectable multiple and bilobarcolorectal liver metastases. Ann Surg2004; 240: 1037-1049.
13. Folprecht G, Grothey A, Alberts S, Raab HR,Köhne CH: Neoadjuvant treatment of unresectableliver metastases: correlation betweentumour response and resection rates.Ann Oncol 2005; 16: 1311-1319.
14. Barone C, Nuzzo G, Cassano A, Basso M,Schinzari G, Giuliante F, D'Argento E, TrigilaN, Astone A, Pozzo C: Final analysis ofcolorectal cancer patients treated with irinotecanand 5-fluorouracil plus folinic acidneoadjuvant chemotherapy for unresectableliver metastases. Br J Cancer 2007; 97: 1035-1039.
15. Alberts SR, Horvath WL, Sternfeld WC,Goldberg RM, Mahoney MR, Dakhil SR,Levitt R, Rowland K, Nair S, Sargent DJ,Donohue JH: Oxaliplatin, fluorouracil, andleucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Groupphase II study. J Clin Oncol 2005; 23: 9243-9249.
16. Ychou M, Viret F, Kramar A, Desseigne F,Mitry E, Guimbaud R, Delpero JR, RivoireM, Quénet F, Portier G, Nordlinger B: Tritherapywith fluorouracil/leucovorin, irinotecanand oxaliplatin (FOLFIRINOX): aphase II study in colorectal cancer patientswith non-resectable liver metastases. CancerChemother Pharmacol 2008; 62: 195-201.
17. Falcone A, Ricci S, Brunetti I, Pfanner E, AllegriniG, Barbara C, Crino L, Benedetti G,Evangelista W, Fanchini L, Cortesi E, PiconeV, Vitello S, Chiara S, Granetto C, Porcile G,Fioretto L, Orlandini C, Andreuccetti M,Masi G, Gruppo Oncologico Nord Ovest:Phase III trial of infusional fluorouracil, leucovorin,oxaliplatin, and irinotecan (FOLFOXIRI)compared with infusional fluorouracil,leucovorin, and irinotecan (FOLFIRI)as first-line treatment for metastaticcolorectal cancer: the Gruppo OncologicoNord Ovest. J Clin Oncol 2007; 25: 1670-1676.
18. Hubbard J, Grothey A: Antiangiogenesisagents in colorectal cancer. Curr Opin Oncol2010; 22: 374-380.
19. Saltz LB, Clarke S, Diaz-Rubio E, ScheithauerW, Figer A, Wong R, Koski S, LichinitserM, Yang TS, Rivera F, Couture F, Sirzen F,Cassidy J: Bevacizumab in combination withoxaliplatin-based chemotherapy as first-linetherapy in metastatic colorectal cancer: arandomized phase III study. J Clin Oncol2008; 26: 2013-2019.
20. Van Cutsem E, Rivera F, Berry S, KretzschmarA, Michael M, DiBartolomeo M, Mazier MA,Canon JL, Georgoulias V, Peeters M, BridgewaterJ, Cunningham D, First BEAT Investigators:Safety and efficacy of first-line bevacizumabwith FOLFOX, XELOX, FOLFIRIand fluoropyrimidines in metastatic colorectalcancer: the BEAT study. Ann Oncol 2009;20: 1842-1847.
21. Okines A, Puerto OD, Cunningham D, ChauI, Van Cutsem E, Saltz L, Cassidy J: Surgerywith curative-intent in patients treated withfirst-line chemotherapy plus bevacizumabfor metastatic colorectal cancer First BEATand the randomized phase-III NO16966 trial.Br J Cancer 2009; 101: 1033-1038.
22. Masi G, Loupakis F, Salvatore L, Fornaro L,Cremolini C, Cupini S, Ciarlo A, Del MonteF, Cortesi E, Amoroso D, Granetto C, FontaniniG, Sensi E, Lupi C, Andreuccetti M, FalconeA: Bevacizumab with FOLFOXIRI (irinotecan,oxaliplatin, fluorouracil, and folinate)as first-line treatment for metastaticcolorectal cancer: a phase II trial. Lancet Oncol2010; 11: 845-852.
23. Chun YS, Vauthy JN, Boonsirikamchai P,Maru DM, Kopetz S, Palavecino M, CurleySA, Abdalla EK, Kaur H, Charnsangaveij C,Loyer EM: Association of computed tomographymorphologic criteria with pathologicresponse and survival in patients treatedwith bevacizumab for colorectal liver metastases.JAMA 2009; 302: 2338-2344.
24. Rubbia-Brandt L, Lauwers GY, Wang H, MajnoPE, Tanabe K, Zhu AX, Brezault C, SoubraneO, Abdalla EK, Vauthey JN, Mentha G,Terris B: Sinusoidal obstruction syndromeand nodular regenerative hyperplasia arefrequent oxaliplatin-associated liver lesionsand partially prevented by bevacizumab inpatients with hepatic colorectal metastasis.Histopathology 2010; 56: 430-439.
25. Ribero D, Wang H, Donadon M, Zorzi D,Thomas MB, Eng C, Chang DZ, Curley SA,Abdalla EK, Ellis LM, Vauthey JN: Bevacizumabimproves pathologic response andprotects against hepatic injury in patientstreated with oxaliplatin-based chemotherapyfor colorectal liver metastases. Cancer2007; 110: 2761-2767.
26. Kishi Y, Zorzi D, Contreras CM, Maru DM,Kopetz S, Ribero D, Motta M, Ravarino N,Risio M, Curley SA, Abdalla EK, CapussottiL, Vauthey JN: Extended preoperative chemotherapydoes not improve pathologic responseand increases postoperative liverinsufficiency after hepatic resection forcolorectal liver metastases. Ann Surg Oncol2010; 17: 2870-2876.
27. van der Pool AE, Marsman HA, Verheij J,Ten Kate FJ, Eggermont AM, Ijzermans JN,Verhoef C: Effect of bevacizumab added preoperativelyto oxaliplatin on liver injury andcomplications after resection of colorectalliver metastases. J Surg Oncol 2012, E-pubahead of print.
28. De Roock W, De Vriendt V, Normanno N,Ciardello F, Tejpar S: KRAS, BRAF andPTEN mutations: implications for targetedtherapies in metastatic colorectal cancer.Lancet Oncol 2011; 12: 594-603.
29. Jacobs B, De Roock W, Piessevaux H, VanOirbeek R, Biesmans B, De Schutter J, FieuwsS, Vandesompele J, Peeters M, Van LaethemJL, Humblet Y, Pénault-Llorca F, De HertoghG, Laurent-Puig P, Van Cutsem E, Tejpar S:Amphiregulin and epiregulin mRNA expressionin primary tumors predicts outcomein metastatic colorectal cancer treatedwith cetuximab. J Clin Oncol 2009; 27: 5068-5074.
30. Baker JB, Dutta D, Watson D, Maddala T,Munneke BM, Shak S, Rowinsky EK, Xu LA,Harbison CT, Clark EA, Mauro DJ, Khambata-Ford S: Tumour gene expression predictsresponse to cetuximab in patients withKRAS wild-type metastatic colorectal cancer.Br J Cancer 2011; 104: 488-495.
31. Van Cutsem E, Köhne CH, Lang I, FolprechtG, Nowacki MP, Cascinu S, Shchepotin I,Maurel J, Cunningham D, Tejpar S, SchlichtingM, Zubel A, Celik I, Rougier P, CiardelloF: Cetuximab plus irinotecan, fluorouracil,and leucovorin as first-line treatment formetastatic colorectal cancer: updated analysisof overall survival according to tumorKRAS and BRAF mutation status. J Clin Oncol2011; 29: 2011-2019.
32. Folprecht G, Gruenberger T, Bechstein WO,Raab HR, Lordick F, Hartmann JT, Lang H,Frilling A, Stoehlmacher J, Weitz J, KonopkeR, Strosczynski C, Liersch T, Ockert D,Herrmann T, Goekkurt E, Parisi F, KöhneCH: Tumour response and secondary resectabilityof colorectal liver metastases followingneoadjuvant chemotherapy with cetuximab:the CELIM randomized phase 2 trial.Lancet Oncol 2010; 11: 38-47.
33. Maughan TS, Adams RA, Smith CG, MeadeAM, Seymour MT, Wilson RH, IdziaszczykS, Harris R, Fisher D, Kenny SL, Kay E,Mitchell JK, Madi A, Jasani B, James MD,Bridgewater J, Kennedy MJ, Claes B,Lambrechts D, Kaplan R, Cheadle JP, MRCCOIN Trial Investigators: Addition of cetuximabto oxaliplatin-based first-line combinationchemotherapy for treatment of advancedcolorectal cancer: results of the randomizedphase 3 MRC COIN trial. Lancet2011; 377: 2103-2114.
34. Tveit KM, Guren T, Glimelius B, Pfeiffer P,Sorbye H, Pyrhonen S, Sigurdsson F, Kure E,Ikdahl T, Skovlund E, Fokstuen T, Hansen F,Hofsli E, Birkemeyer E, Johnsson A, StarkhammarH, Yilmaz MK, Keldsen N, ErdalAB, Dajani O, Dahl O, Christoffersen T:Phase III trial of cetuximab with continuousor intermittent fluorouracil, leucovorin, andoxaliplatin (Nordic FLOX) versus FLOXalone in first-line treatment of metastaticcolorectal cancer: the NORDIC-VII study. JClin Oncol 2012; 30: 1755-1762.
35. Garufi C, Torsello A, Tumulo S, Ettorre GM,Zeuli M, Campanella C, Vennarecci G, MottoleseM, Sperduti I, Cognetti F: Cetuximabplus chronomodulated irinotecan, 5-fluorouracil,leucovorin and oxaliplatin as neoadjuvantchemotherapy in colorectal liver metastases:POCHER trial. Br J Cancer 2010;103: 1542-1547.
36. Aloia T, Sebagh M, Plasse M, Karam V, LéviF, Giacchetti S, Azoulay D, Bismuth H,Castaing D, Adam R: Liver histology andsurgical outcomes after preoperative chemotherapywith fluorouracil plus oxaliplatin incolorectal cancer liver metastases. J Clin Oncol2006; 24: 4983-4990.
37. Karoui M, Penna C, Amin-Hashem M, MitryE, Benoist S, Franc B, Rougier P, NordlingerB: Influence of preoperative chemotherapyon the risk of major hepatectomy forcolorectal liver metastases. Ann Surg 2006;243: 1-7.
38. Kopetz S, Vauthey JN: Perioperative chemotherapyfor resectable hepatic metastases.Lancet 2008; 371: 963-965.
39. Kesmodel SB, Ellis LM, Lin E, Chang GJ, AbdallaEK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW: Preoperativebevacizumab does not significantly increasepostoperative complication rates in patientsundergoing hepatic surgery for colorectalcancer liver metastases. J Clin Oncol 2008;26: 5254-5260.